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Background
Refractory depression is a major contributor to the economic
burden of depression. Radically open dialectical behaviour
therapy (RO DBT) is an unevaluated new treatment targeting
overcontrolled personality, common in refractory depression,
but it is not yet knownwhether the additional expense of RO DBT
is good value for money.
Aims
To estimate the cost-effectiveness of RO DBT plus treatment as
usual (TAU) compared with TAU alone in people with refractory
depression (trial registration: ISRCTN85784627).
Method
We undertook a cost-effectiveness analysis alongside a rando-
mised trial evaluating RO DBT plus TAU versus TAU alone for
refractory depression in three UK secondary care centres. Our
economic evaluation, 12 months after randomisation, adopted
the perspective of the UK National Health Service (NHS) and
personal social services. It evaluated cost-effectiveness by
comparing the net cost of RO DBT with the net gain in quality-
adjusted life-years (QALYs), estimated using the EQ-5D-3L
measure of health-related quality of life.
Results
The additional cost of RO DBT plus TAU compared with TAU
alone was £7048 and was associated with a difference of 0.032
QALYs, yielding an incremental cost-effectiveness ratio (ICER)
of £220 250 per QALY. This ICER was well above the National
Institute for Health and Care Excellence (NICE) upper thresh-
old of £30 000 per QALY. A cost-effectiveness acceptability
curve indicated that RO DBT had a zero probability of being
cost-effective compared with TAU at the NICE £30 000
threshold.
Conclusions
In its current resource-intensive form, RO DBT is not a cost-
effective use of resources in the UK NHS.
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The economic burden of depression is substantial. The total cost of
adult depression across England in 2007 was more than £7.5 billion,
including £1.6 billion for health and social care and £5.8 billion for
loss of earnings.1 Many of these costs are due to refractory depres-
sion or treatment-resistant depression. For example, Crown2 found
that depression-related costs for in-patients with treatment-
resistant depression were 19 times greater than those for other in-
patients, and the costs for out-patients with treatment-resistant
depression were 2.5 times greater than for other out-patients. This
paper evaluates the cost-effectiveness of radically open dialectical
behaviour therapy (RO DBT), a new treatment targeting overcon-
trolled personality, common in refractory depression.3
Method
Design
The Refractory Depression –Mechanisms and Efficacy of Radically
Open Dialectical Behaviour Therapy (RefraMED) study (trial regis-
tration: ISRCTN85784627) included a three-centre parallel-group
randomised trial that compared RO DBT plus treatment as usual
(TAU) with TAU alone and an integrated economic evaluation.
We assessed participants at baseline and 7, 12 and 18 months
after randomisation; the primary end-point of the trial was 12
months after randomisation.
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Participants
Patients were eligible for the RefraMED trial if they: were 18 years or
older; had an IQ >70; spoke English well enough to participate; had
a current diagnosis of major depressive disorder in the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I);4 had
refractory depression, defined below; and had a Hamilton Rating
Scale for Depression (HRSD)5 score of at least 15.
Definitions of refractory depression vary across studies. For
example, Berlim & Turecki6 found more than ten different descrip-
tive terms for treatment-resistant/refractory major depression.
In the present study we define refractory depression as either
chronic depression, that is depression lasting at least 2 years, or treat-
ment-resistant depression, that is recurrent depression (which we
operationalised as two or more previous episodes) which has not
responded to an adequate dose of antidepressant medication for at
least 6 weeks in the current episode.
Interventions
TAU
All participants received TAU, including prescribed antidepressant
medication or psychotherapy.7 In addition, control participants
could access any treatment offered by the UK National Health
Service (NHS) or privately, except standard DBT.
RO DBT
RO DBT is a transdiagnostic therapy designed to address a spec-
trum of disorders that are difficult to treat, in particular chronic
depression.8 It differs from other psychotherapies most notably by
encouraging social bonding through emotional expression and
‘social signalling’, defined as any behaviour that an individual per-
forms in the presence of another person, regardless of intention
or awareness. At the time of the trial, RO DBT comprised 29
weekly individual therapy sessions each lasting 1 h and 27 skills
training classes each lasting 2.5 h.3,8 Although participants contin-
ued to receive antidepressant medication as prescribed, we strongly
discouraged them from seeking additional psychotherapy during
RO DBT. Further information on RO DBT is contained in the clin-
ical paper.9
Economic perspective
The economic perspective was that of the UK NHS and personal
social services, as preferred by the UK National Institute for
Health and Care Excellence (NICE).10 We also explored the add-
ition of productivity losses resulting from time off work due to
illness, in sensitivity analysis.
Method of economic evaluation
The primary method of economic evaluation was cost–utility ana-
lysis, with effects measured in quality-adjusted life-years (QALYs),
as preferred by NICE.10 We also undertook a cost-effectiveness ana-
lysis, with effects measured in terms of depressive symptoms, the
primary outcome of the RefraMED trial.
Outcomes
For our primary economic evaluation, we estimated QALYs using
the EQ-5D-3L measure of health-related quality of life.11 The
EQ-5D-3L is a generic, preference-based measure for describing
and valuing health-related quality of life.11 It rates health in five
domains – mobility, self-care, usual activities, pain or discomfort,
and anxiety or depression. The health states described in the
EQ-5D-3L were assigned a utility weight or score using responses
from a representative sample of adults in the UK.12 These weights
were applied to the time between interviews and QALYs calculated
using the area under the curve approach.13 The EQ-5D has been
validated in economic evaluations for common mental health
disorders.14 For our secondary economic evaluation, effects were
measured in terms of depression using the HRSD,5 which was the
primary clinical outcome of the RefraMED trial.
Resource use
We collected resource-use data using a version of the Adult Service
Use Schedule (AD-SUS)15 designed for populations with depres-
sion. Research assessors completed this in interview with partici-
pants and recorded all use of hospital and community-based
health and personal social care. For medications, we asked partici-
pants to report prescribed antidepressants, antipsychotics, sleeping
tablets and painkillers. To avoid unmasking of research assessors,
participants reported their use of all talking therapies on a separate
self-reported questionnaire. We collected information about time
off work due to illness alongside the AD-SUS using the productivity
questions from the World Health Organization Health and Work
Performance Questionnaire (HPQ).16 We asked participants to
complete the AD-SUS and HPQ at baseline, to cover the previous
6 months, and at the 7-, 12- and 18-month interviews, to cover
the time since the previous interview, thus covering the full
period from baseline to final follow-up. We abstracted information
on RO DBT resource use, including the number of individual and
group sessions attended by each participant, from therapy records.
Unit costs
With the exception of RO DBT, we estimated mean costs of health
and social services for each group by multiplying participants’
reported use by unit costs from national sources.17–19 All unit costs,
summarised in supplementary Table 1 (available at https://doi.org/
10.1192/bjo.2019.57), were for the financial year 2014–2015,
uprated where necessary using the Hospital and Community
Health Services Index.17 We based medication costs on the median
dose of the most common category of drug (e.g. antidepressant,
antipsychotic) reported by participants. We used participant-
reported start and finish dates to estimate duration of their time
using that drug, assuming full adherence. We estimated the costs
of depression-related absenteeism and presenteeism for participants
in paid employment using the human capital approach based on the
national gross average wage.20,21
We estimated RO DBT costs using the micro-costing approach
developed by the Personal Social Services Research Unit (PSSRU) at
the University of Kent.22 We costed individual sessions from the
average therapist Agenda for Change salary bands, including
employer’s costs (national insurance and pension contributions)
and overhead costs (buildings, utilities, management and adminis-
tration) from national sources.17,23 We weighted salary costs to
cover therapists’ time away from their own patients using informa-
tion from 16 RO DBT therapists on the time they spent running
RO DBT therapy sessions and on other activities, which suggested
a direct:non-direct ratio of 1:0.91. Individual sessions lasted
60 min on average. Supplementary Table 2 details our method of
valuing therapist time.
We costed RO DBT group sessions on the basis that they were
closed to other patients and went ahead irrespective of how many
participants attended.24 We allocated the total cost of each group
session across all participants invited to attend, regardless of
whether or not they did attend. Group sessions lasted 2.5 h on
average. The number of therapists running groups varied by
group size. Groups larger than three patients were typically run
by two therapists. The valuation of the cost of these group sessions
is summarised in supplementary Table 3.
Shearer et al
2
We did not include DBT-specific training costs because
equivalent costs for the control group could not be easily identified
and costed, making comparison difficult. In clinical practice,
therapists undertake a wide range of training as part of profes-
sional development. It is therefore reasonable to assume that RO
DBT training, if rolled out, would form part of this professional
development in the same way as training received in other therap-
ies, such as cognitive–behavioural therapy (CBT). Similarly, we
excluded from analysis the cost of participants who failed to
attend RO DBT individual sessions, given the absence of equiva-
lent data for the control group. Only when comparing two specific
therapies is it possible to record and cost non-attendance for both
groups. In this study TAU varied; thus, participants reported
attendances with therapists and other health professionals, but
not non-attendances. Furthermore, we assumed that therapists
would undertake other work activities during the time freed by
non-attendances, thus reducing the cost of those non-attendances,
potentially to zero.
Statistical analysis
Costs and outcomes
We initially present descriptive data on costs and outcomes
adjusted for baseline differences in costs and relevant outcomes
plus pre-specified clinical predictors as outlined in the accom-
panying clinical paper.9 We adjusted cost-effectiveness analyses
for the same pre-specified clinical predictors and baseline values
of the variables of interest (costs, EQ-5D-3L or HRSD). We ana-
lysed cost differences by t-tests with confidence intervals around
adjusted mean differences estimated using non-parametric boot-
strapping to reflect non-normality of cost data.25 We imputed
missing cost, QALY and HRSD data using ‘multiple imputation
using chained equations’ (MICE), under the assumption that
these data were missing at random.26 We set the number of multi-
ply imputed data-sets (m) to be equal to the fraction of incomplete
service-use information (30%; m = 30) at the 12-month follow-up,
as recommended by White and colleagues.26 Multiple imputation
reports the sensitivity of results to missing data and the assump-
tion that the data are missing at random. There is evidence that
multiple imputation provides less biased estimates of costs and
effects than complete case analysis, unless data are missing not
at random.26 We set the number of bootstrap replications to
1000 for each of the 30 multiply imputed data-sets (30 000 boot-
strap replications).27
Cost-effectiveness analysis
We conducted the pre-specified primary cost-effectiveness analysis
after 12 months, as with the clinical analyses. We assessed cost-
effectiveness by estimating incremental cost-effectiveness ratios,
which divide the difference in costs between two interventions by
the difference in outcomes.28 We did not conduct a power calcula-
tion for the cost-effectiveness analysis because this is problematic
owing to the large variability in resource use and cost measures,
and the complexity of forecasting the joint distribution of the differ-
ence in costs and benefits between treatment arms. Instead we fol-
lowed recommendations to take a decision-making approach and
focus on estimating cost and QALY differences, and estimating
the likelihood that RO DBT is cost-effective compared with TAU,
given the data available.29 We generated the joint distribution of
incremental mean costs and effects for RO DBT relative to TAU
using non-parametric bootstrapping to explore the probability that
one of the groups is the better choice given NICE’s ‘willingness-to-
pay’ threshold of £20 000–£30 000 per QALY. We characterised
uncertainty in the cost and effectiveness estimates by cost-effective-
ness acceptability curves.30
Sensitivity analysis
We conducted five sensitivity analyses to explore the impact of var-
iations in methods and assumptions on the relative cost-effective-
ness of RO DBT and TAU:
(a) a complete case analysis for comparison with the results using
multiple imputation for missing data;
(b) a broader economic perspective, additionally including the cost
of absenteeism from work, given that depression is known to
have a substantial effect on employment;31
(c) adjustment of the cost of RODBT group sessions to address the
fact that group session attendance was particularly low and thus
costs particularly high relative to the cost of groups reported in
similar studies; on the assumption that group attendance is
unlikely to be as low in routine NHS services, we replaced the
estimated cost of the RO DBT groups with the national cost
applied to participants reporting group therapy attendances
(£14 rather than £99);
(d) analysis of cost-effectiveness after 18 months to explore over a
longer period the effect of RO DBT relative to TAU;
(e) analysis of cost-effectiveness using cost per point difference in
the primary clinical outcome, the HRSD, as the measure of
effect.
Ethical approval and conduct
Before starting the trial we gained approval from the Hampshire
Research Ethics Committee (National Research Ethics Service
(NRES) reference 11/SC/0146) and the Research Governance
Department of the University of Southampton, the sponsor of this
trial. We asked trial participants for consent on three occasions:
oral before telephone screening; signed before baseline assessment;
and signed before randomisation.
Patient and public inclusion
The National Institute for Health Research (NIHR) Mental Health
Research Network and ‘Involve’, the national advisory group on
public engagement, helped us to recruit two patients to the Trial
Steering Group and two to the Trial Management Group. They con-
tributed to developing patient information leaflets, managing the
trial and disseminating its findings.
Data availability
All non-confidential data and syntax for analyses reported here are
available online (https://zenodo.org/record/1442883).
Results
Participants
We randomised 250 eligible patients, 162 (65%) to RO DBT and 88
(35%) to control. Recruitment started in Dorset in March 2012 with
an internal pilot. Recruitment in Hampshire and North Wales
started in September 2012. Recruitment at all three centres contin-
ued until April 2015. Of the full sample of 250, 164 (66%) were
female; 138 (55%) were aged between 35 and 55; 232 (97% of 238
responders) were White; 106 (42%) reported being in a stable rela-
tionship; and 82 (34% of 241 responders) had a university qualifica-
tion. Ninety-two participants (37%) reported a first depressive
episode before the age of 16; 179 (84% of 213 responders) were
chronically rather than recurrently depressed; and 191 (82% of
234 responders) had previously received psychotherapy. In add-
ition, 198 (79% of the sample) met criteria for a comorbid person-
ality disorder. Full details of the flow of participants through the
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RefraMED trial and their baseline demographic and clinical charac-
teristics are contained in the accompanying clinical paper.9
Missing data
At 12-month follow-up, full service-use data for the entire follow-up
period were available for 125 participants (77%) in the RO DBT
group and 61 (69%) in the TAU group. This is compared to com-
plete data in the RO DBT group for 118 (73%) at 7 months and
for 101 (62%) at 18 months and in the TAU group for 61 (69%)
at 7 months and for 51 (58%) at 18 months. There were no statistic-
ally significant differences between groups in the proportion of
missing data (χ2 = 0.25, P = 0.61). Missing resource-use items in
completed questionnaires were assumed to indicate no service use
and were given a zero value.
Resource use
Resource use over the follow-up period is summarised in supple-
mentary Table 4. Participants enrolled in the RO DBT group
attended an average of 22.8 (median 26) individual RO DBT ses-
sions and 19.3 (median 22.5) group RO DBT sessions. In addition,
they attended an average of 3.4 (median 0) sessions of other types of
talking therapy. Participants in the TAU group attended an average
of 9.1 (median 6.5) sessions of various talking therapies. The use of
all other health and social care services, including medications, was
broadly similar between the two groups, suggesting that group allo-
cation did not have a substantial effect on the intensity of other
service use. Days reported off work and unproductive working
hours were also similar between the two groups.
Costs
Table 1 summarises health and social care costs from the NHS
and personal social services perspective over the 6 months prior
to trial entry and over the 12- and 18-month follow-up periods.
Disaggregated costs are based on complete case data, as data imput-
ation was conducted at the aggregate level. The cost of all health and
social care services used over the 6 months before entry into the trial
were lower in the RO DBT group compared with the TAU group,
but the difference was not significant (mean difference −£1029,
bootstrap 95% CI −£2465 to £407; P = 0.160). Excluding the cost
of RO DBT, the cost of all health and social care services used
was lower over the 12-month follow-up period in the RO DBT
group compared with the control group (adjusted mean difference
−£909, bootstrap 95% CI −£1799 to −£19; P = 0.045) and also
over the 18-month follow-up period (adjusted mean difference
−£901, bootstrap 95% CI −£2755 to £952; P = 0.340). The
RO DBT intervention cost approximately £5000 per person, includ-
ing the cost of both individual and group sessions, resulting in total
costs that were significantly higher in the RO DBT group compared
with TAU over both the 12-month follow-up period (adjusted mean
difference £4566, bootstrap 95%CI £3691–£5440; P < 0.001) and the
18-month follow-up period (adjusted mean difference £4463, boot-
strap 95% CI £2915–£6011; P < 0.001).
Outcomes
Mean EQ-5D-3L scores and QALYs are presented in Table 2, together
with unadjusted differences, differences after adjustment and imput-
ation for missing data. EQ-5D-3L scores improved in both groups
over the 18-month follow-up. Over the 7- and 12-month follow-up
periods, EQ-5D-3L scores and QALYs were slightly higher in the
RO DBT group compared with the TAU group, but over 18 months
of follow-up, they were slightly higher in the TAU group.
Differences were small and non-significant at all follow-up points.
Cost-effectiveness
The base-case 12-month additional cost of RODBT plus TAU com-
pared with TAU alone was £7048, which was associated with a dif-
ference of 0.032 QALYs, yielding an incremental cost-effectiveness
ratio (ICER) of £220 250 per QALY. This ICER was well above the
NICE upper threshold of £30 000 per QALY.
The cost-effectiveness plane shown in Fig. 1 illustrates the
scatterplot of 30 000 bootstrapped cost and effectiveness pairs for
RO DBT versus TAU from the perspective of NHS and personal
social services at the primary 12-month end-point. All scatter
points lie above the x-axis, illustrating that total health and social
care costs are higher for the RO DBT group than the TAU group
in all cases. The majority of scatter points fall in the north-east
quadrant, where RO DBT is more effective than TAU but also
more costly. Uncertainty in the ICER was explored in a cost-effect-
iveness acceptability curve (CEAC) shown in Fig. 2. This illustrates
that RODBT in its current format has zero probability of being cost-
effective compared with TAU at the NICE willingness-to-pay
threshold of £30 000.
Sensitivity analyses
We based the primary economic analysis on a cost–utility analysis
conducted at the 12-month follow-up, from the perspective of
NHS and personal social services, with imputation of missing
data. Supplementary Table 5 summarises how variation in
methods and assumptions affected the ICERs. In sensitivity analyses
1 to 4 (complete case, inclusion of productivity losses, reduction in
the cost of RO DBT group sessions and analysis at the 18-month
follow-up), with all other factors being equal to the base case,
RO DBT remained cost-ineffective compared with TAU, with
costs per QALY all well above the NICE threshold of £30 000 per
QALY. For illustration, replication of the analysis at the
18-month follow-up is reported in supplementary Figs 1 and
2. The results were very similar to those at the 12-month follow-
up, with all replications in the scatter plot (supplementary Fig. 1)
falling above the threshold willingness to pay of £30 000 per
QALY and the CEAC (supplementary Fig. 2) indicating a zero prob-
ability that RO-DBT was cost-effective compared with TAU. In the
final scenario, we undertook a cost-effectiveness analysis using the
primary clinical outcome (the HRSD score) as the measure of
effect, with all other factors being equal to the base-case analysis.
This yielded an ICER of £7048 per unit improvement on the
HRSD. Supplementary Fig. 3 illustrates the scatterplot of 30 000
bootstrapped cost and effectiveness pairs for RO DBT versus
TAU based on differences in HRSD score using the £1000 per
HRSD point threshold proposed by Romeo and colleagues.32 The
results were also very similar to the cost–utility analysis, with all
replications falling above the threshold willingness to pay and the
CEAC indicating a zero probability that RO DBT was cost-effective
compared with TAU (supplementary Fig. 4).
Discussion
Main findings
Our clinical report indicated that RO DBT achieved moderate but
not statistically significant improvement in depressive symptoms
in a highly problematic treatment group.9 This economic analysis
adds important information about whether the moderate gains
might still be a worthwhile use of scarce NHS resources. RO DBT
with TAU was not cost-effective compared with TAU alone in the
treatment of people with refractory depression, either from the per-
spective of the NHS and personal social services or when
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productivity losses were included. RO DBT is a resource-intensive
intervention that does not achieve sufficient gains in outcomes or
savings in the use of other health and social services to justify the
additional cost of the intervention over the cost of TAU. Cost-inef-
fectiveness was driven by the high amount of contact time in RO
DBT, some of whichmay have been an artefact of the rigour of a clin-
ical trial. Whether such an intensive service would be made available
in routine mental health services in the UK NHS is debatable.
Comparison with previous economic studies of DBT for
disorders of overcontrol
This is the first economic evaluation of RO DBT for depression and
one of very few studies to explore the economic implications of a
DBT-informed approach for disorders of overcontrol. Previous eco-
nomic evaluations have focused on standard DBT for borderline
personality disorder (BPD). One economic study alongside a rando-
mised trial compared standard DBT with TAU for self-harming
patients with BPD.33 Although it focused on the cost of the
intervention and other health and social care and did not include
a formal cost-effectiveness analysis, it is a useful comparator. The
mean costs of health and social care over 12 months for the BPD
population (intervention group about £2500 per patient; control
group about £3400) were similar to those of our depression popula-
tion (intervention group about £2200; control group about £3500).
The cost of standard DBT (£3200 per patient) was lower than the
cost of RO DBT in the current study (£5000) but still substantially
higher than that of therapies provided by the UKNHS, such as CBT.
The authors33 concluded that standard DBT was effective in redu-
cing self-harm in people with BPD but acknowledged that it
would incur higher costs.
The remaining four economic evaluations were all part of a sys-
tematic review and preliminary economic evaluation of evidence for
psychological therapies for BPD.34 They used clinical data from four
randomised trials of standard DBT for BPD, and cost data from the
trials where available and other published sources where necessary.
Two evaluations suggested that standard DBT dominated the com-
parison arm (TAU in one study, person-centred therapy in the
Table 1 Disaggregated health and social care costs by group at baseline, 12- and 18-month follow-up
RO DBT (£) Mean (s.d.) TAU (£) Mean (s.d.) Mean differencea (£) 95% CIa (£) Pa
Baseline N = 162 N = 88
Talking therapy 364 (795) 692 (1112)
Hospital services 1305 (4280) 1968 (5140)
Community services 713 (733) 755 (852)
Medications 17 (12) 19 (11)
Total NHS/PSS costs 2397 (4418) 3426 (5812) −1029 −2463 to 407 0.160
Absenteeism 3821 (5563) 4648 (6277)
Presenteeism 3382 (1749) 2676 (2771)
Total societal costs 9600 (6469) 10 750 (8354) −1830 −3763 to 104 0.064
Baseline to month 12 N = 125 N = 61
RO DBT individual 3095 (1095) 0 (0)
RO DBT groups 1910 (817) 0 (0)
Total RO DBT 5005 (1809) 0 (0)
Talking therapy 256 (137) 1317 (2388)
Hospital services 934 (1803) 1216 (2400)
Community services 986 (1527) 966 (1411)
Medications 29 (18) 35 (20)
Total NHS + PSS costs 7210 (3343) 3534 (4240) 4566 3691 to 5440 <0.001
Absenteeism 2415 (5248) 4063 (9145)
Presenteeism 5641 (2662) 4827 (2419)
Total societal costs 15 266 (5072) 12 424 (6764) 2657 1217 to 4098 <0.001
Baseline to month 18 N = 101 N = 51
Talking therapy 501 (253) 1633 (1561)
Hospital services 1419 (1824) 2004 (1793)
Community services 1419 (1824) 1407 (2399)
Medications 45 (46) 55 (48)
Total NHS/PSS costs 8389 (4357) 5099 (7677) 4463 2915 to 6011 <0.001
Absenteeism 4050 (9616) 5833 (13 224)
Presenteeism 7634 (6925) 7718 (7818)
Total societal costs 20 073 (6967) 18 650 (12 262) 1062 −1762 to 3886 0.461
NHS, National Health Service; PSS, personal social services; RO DBT, radically open dialectical behaviour therapy; TAU, treatment as usual.
a. All analyses adjusted and bootstrapped.
Table 2 EQ-5D-3L scores and QALYs at baseline, 12- and 18-month follow-up
RO DBT Mean (s.d.) TAU Mean (s.d.) Mean differencea 95% CIa Pa
EQ-5D-3L
Baseline 0.422 (0.291) 0.395 (0.329) –
12-month 0.552 (0.339) 0.547 (0.307) 0.008 −0.074 to 0.090 0.847
18-month 0.564 (0.311) 0.596 (0.309) 0.005 −0.087 to 0091 0.096
QALYs
12-month 0.534 (0.315) 0.496 (0.349) 0.032 −0.029 to 0.093 0.297
18-month 0.702 (0.067) 0.763 (0.453) 0.023 −0.074 to 0.114 0.677
QALY, quality-adjusted life-year; RO DBT, radically open dialectical behaviour therapy; TAU, treatment as usual.
a. All analyses adjusted, imputed and bootstrapped.
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other), achieving better outcomes at a lower cost per patient. The
third evaluation found slightly higher costs but better outcomes in
terms of parasuicides avoided for standard DBT compared with
TAU. The fourth evaluation found that standard DBT was more
costly than TAU but delivered only moderate gains in outcomes
(parasuicide events avoided and QALYs) at an ICER considerably
above the NICE threshold. All these analyses showed considerable
uncertainty because they analysed data from only 20–44 patients.
Furthermore, they relied heavily on assumptions and data outside
the original trials, since none of them included economic data.
The authors34 concluded that the findings did not support the
cost-effectiveness of standard DBT for BPD, although it has the
potential to be cost-effective.
In comparison, the RefraMED economic evaluation provides
rigorous economic evidence about RO DBT in the NHS using
NICE criteria established for clinical disorders. Interestingly,
when it comes to treatment recommendations for personality disor-
ders, NICE is equivocal about cost estimates. Despite costs for out-
patient DBT far exceeding recommended thresholds, NICE34 still
recommends DBT for treatment of BPD in the NHS. As noted by
NICE,34 costing thresholds for the treatment of personality disor-
ders have yet to be identified and broad consensus has been repeat-
edly noted for a change in how we measure and pay for mental
healthcare in the NHS – especially when it comes to treating
chronic mental health problems.35 The high rates of comorbid per-
sonality disorder (79%) in the RefraMED trial suggest that cost con-
siderations for our trial – and other similar trials in chronic
depression – may be best understood when evaluated similarly.
Study limitations
The interpretation of our economic results is subject to some
important limitations. First, in terms of generalisability, there is a
range of definitions of refractory depression and treatment-resistant
depression, which should be taken into account when considering
the generalisability of our findings. Second, our economic findings
may also have limited generalisability outside NHS mental health
services in England and Wales. Third, the study fell short of the
target recruitment (250/276, 91%) and full follow-up data for
the economic evaluation were available for only 74% (186/250) of
the sample; consequently, the study was underpowered with
respect to the pre-planned target effect size.3
Implications for further research
Since our results suggest that RODBT in its current form is not cost-
effective relative to TAU according to NICE criteria, research should
address how to refine RO DBT to maintain the present gains but at
lower cost for longer. There are many ways of adjusting the delivery
of RODBT to reduce costs, and future work must address the effect-
iveness and cost-effectiveness of these amended manuals. For
example, we could taper treatment by reducing the frequency of ses-
sions after an initial intensive period or adopt a stepped approach
offering group sessions initially and individual sessions only to
those who fail to respond. Indeed, small studies of RO DBT skills
training classes have reported promising improvements in
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effectiveness.36,37 Another important avenue of future research will
be the development and evaluation of a RO DBT support pro-
gramme on mobile phones or the internet. Several participants sug-
gested that this would be helpful during and after active treatment.
Further exploratory analyses of the RefraMED data-set will be crit-
ical in developing a shorter version of the skills programme that
could be used in NHS settings with limited funding.
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